PPMonitor checks laboratory air quality
Enables effective and flexible management of indoor air quality
The PPMonitor, from the Caernarfon, Wales firm, can continuously detect, measure and record temperature, humidity, formaldehyde, nitrogen dioxide, carbon monoxide, carbon dioxide, sulphur dioxide, ozone, ammonia and TVOCs.
The device incorporates a variety of advanced gas sensor technologies to monitor the target gases including NDIR, PID and electrochemical sensors.
The wireless units communicate via the Zigbee wireless mesh network, which can be extended by adding repeater nodes or additional PPMonitor or Mini PPMonitor units. Each unit can be configured with unique sensor specifications if required, allowing complete monitoring of the cleanroom air environment.
PPMonitor Units can be wirelessly connected to a Building Management System, in which BMS software allows the entire wireless system to be managed from a single PC. The BMS can activate and control air conditioning and ventilation systems; it can also turn on/off heating and trigger building alarms, if required.
All recorded data is stored automatically with dedicated software, which enables the data to be viewed graphically and produces reports and statistical data. Analysis of the recorded data over time allows for more efficient management of resources and energy.
You may also like
Manufacturing
![Why CAPA keeps failing and what strong organisations do differently]()
Why CAPA keeps failing and what strong organisations do differently
Read moreThis white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
![Why CAPA keeps failing and what strong organisations do differently]()
Why CAPA keeps failing and what strong organisations do differently
This white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part II)]()
Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part II)
How a centralised qualification matrix reconciles vendor documentation, integrates risk-based verification and connects commissioning findings with deviation, CAPA and audit-ready evidence
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
![Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part I)]()
Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part I)
Documentation Specialist Snehal Godse explains why unit-level FAT and SAT leave critical multivendor interfaces unverified and proposes a risk-based framework to qualify product transfers, control signals, interlocks, sensors and shared utilities
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Research grade to GMP: how peptide quality requirements change as development progresses]()
Research grade to GMP: how peptide quality requirements change as development progresses
This article presents a practical guide to matching peptide characterisation, impurity control, traceability and manufacturing oversight with rising regulatory expectations across preclinical and clinical development
